The Human Immunodeficiency Virus (HIV) is thought to be the primary cause of one of the most severe and chronic diseases, known as Acquired Immunodeficiency Syndrome (AIDS). It is a viral infection that spreads through contact with blood, semen, breast milk, and other agents that have HIV infected them. HIV infection rates are increasing dramatically. The World Health Organization (WHO) estimates that 33.0 million people worldwide are HIV-positive at this time. People are now more and more conscious of this, which has increased the number of testing processes. High-potency HIV drugs are now in high demand for the treatment and management of the condition as a result of this.
Market Size and Key Findings
The Global HIV Therapeutics size is at around US $ xx Bn in 2021 and is projected to reach US $ xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period.
Global HIV Therapeutics Size (In USD Bn)
(2021-2030F)
Market Dynamics
Market Growth Drivers Analysis
The development of new testing methods such as quick POC testing, ELSIA, and viral load testing, as well as improvements in HIV diagnostic testing, have opened up the attractive potential for the market's major players. Over the forecast period, the market for HIV medicines is likely to grow even more. Self-testing kits and HIV testing kits are becoming increasingly popular, which offers several chances for market expansion for the major competitors. The Global market for HIV treatments has significant potential as mobile diagnostics instruments are being adopted in developing nations to identify HIV.
Market Restraints
The market expansion is being constrained by a few restraint factors despite improvements in research and development, increased scientific understanding of HIV, and the availability of treatment options. Many persons who are HIV-positive or at risk of contracting the virus do not have access to prompt care. Additionally, this virus still has no known treatment. For instance, there is an uneven distribution of treatment measures around the world, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). The lack of suitable treatment choices continues to be a problem in middle-income and developing nations, which would restrain the expansion of the HIV medicine market.
Competitive Landscape
Key Players
The prominent players operating in this market include Gilead Sciences, Inc. (US), AbbVie Inc (US), Galderma SA (Switzerland), Johnson & Johnson (US), Cipla (India), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Co. (US), Teva Pharmaceutical Industries Ltd. (Israel), ViiV Healthcare (UK) and GlaxoSmithKline PLC (UK)
TABLE OF CONTENT
1. Report Description of the Global HIV Therapeutics
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. Global HIV Therapeutics Executive Summary
2.1 Global HIV Therapeutics – Industry Snapshot & key buying criteria, 2021-2030
2.2 Market Size, Growth Prospects, and Key findings
